

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 15 of 15 returned.**☐ 1. Document ID: US 20010053792 A1

L1: Entry 1 of 15

File: PGPB

Dec 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010053792

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010053792 A1

TITLE: Method for reducing postprandial oxidative stress using cocoa procyanidins

PUBLICATION-DATE: December 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schmitz, Harold H.	Branchburg	NJ	US	
Romanczyk, Leo J. JR.	Hackettstown	NJ	US	

US-CL-CURRENT: 514/453; 424/440, 426/660

ABSTRACT:

A method for reducing postprandial oxidative stress and associated pathologies by the dietary intake of cocoa procyanidins, such as epicatechin is disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC
Draw Desc	Image										

☐ 2. Document ID: US 20010041726 A1

L1: Entry 2 of 15

File: PGPB

Nov 15, 2001

PGPUB-DOCUMENT-NUMBER: 20010041726

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010041726 A1

TITLE: Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

PUBLICATION-DATE: November 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bandarage, Ramani R.	Newton	MA	US	
Bandarage, Upul K.	Newton	MA	US	
Fang, Xinqin	Lexington	MA	US	
Garvey, David S.	Dover	MA	US	
Letts, L. Gordon	Dover	MA	US	
Schroeder, Joseph D.	Dedham	MA	US	
Tam, Sang William	Dover	MA	US	

US-CL-CURRENT: [514/361](#); [514/249](#), [548/127](#), [548/250](#), [548/360.1](#)

ABSTRACT:

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B.sub.4 (LTB.sub.4) receptor antagonists, leukotriene A.sub.4 (LTA.sub.4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 6309888 B1

L1: Entry 3 of 15

File: USPT

Oct 30, 2001

US-PAT-NO: 6309888

DOCUMENT-IDENTIFIER: US 6309888 B1

TITLE: Detection and determination of the stages of coronary artery disease

DATE-ISSUED: October 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Holvoet; Paul N.	Kessel-Lo			BEX
Collen; Desire J.	London			GBX

US-CL-CURRENT: [436/71](#); [435/7.1](#), [435/7.2](#), [435/7.21](#), [435/7.92](#), [435/7.93](#), [435/7.94](#), [435/7.95](#), [435/967](#), [435/973](#), [436/13](#), [436/15](#), [436/540](#), [436/546](#), [436/548](#), [436/809](#),

530/380, 530/388.1, 530/388.15, 530/388.25

ABSTRACT:

A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

54 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 4. Document ID: US 6288106 B1

L1: Entry 4 of 15

File: USPT

Sep 11, 2001

US-PAT-NO: 6288106

DOCUMENT-IDENTIFIER: US 6288106 B1

TITLE: Processes for the synthesis and use of various .alpha.-lipoic acid complexes

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pearson; Don C.	Lakewood	WA		
Richardson; Kenneth T.	Anchorage	AK		

US-CL-CURRENT: 514/440; 549/39

ABSTRACT:

This invention is in the fields of pharmacology and biochemistry. It relates to processes for the synthesis of certain complexes of .alpha.-lipoic acid and the nutritional or therapeutic use of these and other related individual or complexed antioxidant, proglutathione molecules. Therapeutic uses for these molecules and complexes in the clinical management of conditions and functions associated with chronic glaucoma, insulin resistance, macular degeneration, lenticular cataract, neurodegenerative diseases, essential hypertension, atherosclerosis and vasoconstriction are described in particular.

15 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 5. Document ID: US 6207702 B1

L1: Entry 5 of 15

File: USPT

Mar 27, 2001

US-PAT-NO: 6207702

DOCUMENT-IDENTIFIER: US 6207702 B1

TITLE: Method for reducing postprandial oxidative stress using cocoa procyanidins

DATE-ISSUED: March 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmitz; Harold H.	Branchburg	NJ		
Romanczyk, Jr.; Leo J.	Hackettstown	NJ		

US-CL-CURRENT: 514/453; 424/776, 426/479, 426/593, 426/631, 426/655, 426/72, 426/804, 514/456

ABSTRACT:

A method for reducing postprandial oxidative stress and associated pathologies by the dietary intake of cocoa procyanidins, such as epicatechin is disclosed.

32 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 6. Document ID: US 6096556 A

L1: Entry 6 of 15

File: USPT

Aug 1, 2000

US-PAT-NO: 6096556

DOCUMENT-IDENTIFIER: US 6096556 A

TITLE: Method for the determination of oxidative stress

DATE-ISSUED: August 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heinecke; Jay W.	St. Louis	MO		

US-CL-CURRENT: 436/89

ABSTRACT:

A noninvasive method for the determination of oxidative stress in a patient is disclosed. The method comprises quantifying the levels or relative distribution of a pair of compounds, o,o'-dityrosine and o-tyrosine, in a sample of the patient's urine

and comparing with the corresponding levels or relative distribution of the compounds in a normal or control sample.

8 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 7. Document ID: US 5945295 A

L1: Entry 7 of 15

File: USPT

Aug 31, 1999

US-PAT-NO: 5945295

DOCUMENT-IDENTIFIER: US 5945295 A

TITLE: Method and compositions to detect autooxidation of lipids or fats ex vivo

DATE-ISSUED: August 31, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roberts, II; L. Jackson	Nashville	TN		
Morrow; Jason D.	Nashville	TN		
Kuhrts; Eric H.	Woodside	CA		

US-CL-CURRENT: 435/7.92; 435/25, 435/63, 436/71, 436/74, 562/503

ABSTRACT:

This invention relates to a method to assess food spoilage ex vivo by quantification of prostanoid compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.

9 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 8. Document ID: US 5891622 A

L1: Entry 8 of 15

File: USPT

Apr 6, 1999

US-PAT-NO: 5891622

DOCUMENT-IDENTIFIER: US 5891622 A

TITLE: Assessment of oxidative stress in vivo

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morrow; Jason D.	Nashville	TN		
Kim; Hyesook	Bloomfield Hills	MI		
Roberts, II; L. Jackson	Nashville	TN		
Callewaert; Denis M.	Oxford	MI		

US-CL-CURRENT: 435/4; 435/25, 435/29

ABSTRACT:

A method to assess oxidative stress in vivo by measuring the amount of free, esterified and glucuronidated forms of isoprostanes (8EPGF2) in a biological sample which contains the isoprostanes is disclosed. The method further includes determining the amount of total isoprostanes present in the sample. This amount is compared with a control sample. The oxidative stress is determined through the comparison wherein the amount of isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control. Alternatively the method of the present invention provides for only the measurement of the glucuronidated form wherein the amount of glucuronidated isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control.

10 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 9. Document ID: US 5858696 A

L1: Entry 9 of 15

File: USPT

Jan 12, 1999

US-PAT-NO: 5858696

DOCUMENT-IDENTIFIER: US 5858696 A

TITLE: Method and compositions to assess oxidative stress in vivo

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roberts, II; L. Jackson	Nashville	TN		
Morrow; Jason D.	Nashville	TN		

US-CL-CURRENT: 435/25; 435/63, 436/71, 436/74, 562/503

ABSTRACT:

This invention relates to a method to assess oxidative stress in vivo by quantification of prostaglandin F.sub.2-like compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.

10 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 10. Document ID: US 5829449 A

L1: Entry 10 of 15

File: USPT

Nov 3, 1998

US-PAT-NO: 5829449

DOCUMENT-IDENTIFIER: US 5829449 A

TITLE: Smoking products containing antioxidants

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hersh; Theodore	Atlanta	GA		
Hersh; Rebecca	Atlanta	GA		

US-CL-CURRENT: 131/202; 131/298, 131/331, 131/334

ABSTRACT:

A composition for inclusion within a cigarette, cigar or pipe. The composition can be included within the tobacco itself, a filter for filtering tobacco smoke once burned or even within the paper or wrapper surrounding the tobacco product. The composition is capable of reducing free radical damage to the oro-pharyngeal cavity, respiratory tract and lungs resulting from tobacco smoke. The composition includes L-glutathione and a source of selenium such as selenomethionine.

47 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 11. Document ID: US 5747533 A

L1: Entry 11 of 15

File: USPT

May 5, 1998

US-PAT-NO: 5747533

DOCUMENT-IDENTIFIER: US 5747533 A

TITLE: Use of .omega.-3-fatty acids

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Egberg; Nils	Lidingo			SEX
Larsson-Backstrom; Carin	Stockholm			SEX
Jakobsson; Jan	Djursholm			SEX
Lundh; Rolf	Huddinge			SEX

US-CL-CURRENT: 514/549; 514/458, 514/474, 514/560, 514/725

ABSTRACT:

The present invention relates to omega-3-fatty acid containing preparations for the treatment of Disseminated Intravascular Coagulation (DIC) and symptoms related to DIC, as well as such preparations for reducing a pathological increase in pulmonary artery pressure (PAP). The preparations may be in the form of emulsions, or aerosols for inhalation, of an oil or phospholipids or other derivatives or salts of omega-3-fatty acids of marine and/or vegetable origin with a significant content of omega-3-fatty acids. The preparations may also be in tablet or capsule form for oral use.

20 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 12. Document ID: US 5731346 A

L1: Entry 12 of 15

File: USPT

Mar 24, 1998

US-PAT-NO: 5731346

DOCUMENT-IDENTIFIER: US 5731346 A

TITLE: Use of omega-3-fatty acids

DATE-ISSUED: March 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Egberg; Nils	Lidingo			SEX
Larsson-Backstrom; Carin	Stockholm			SEX
Jakobsson; Jan	Djursholm			SEX
Lundh; Rolf	Huddinge			SEX

US-CL-CURRENT: 514/549; 514/458, 514/474, 514/560, 514/78, 514/824

ABSTRACT:

The present invention relates to omega-3-fatty acid containing preparations for the treatment of Disseminated Intravascular Coagulation (DIC) and symptoms related to DIC, as well as such preparations for reducing a pathological increase in pulmonary artery pressure (PAP). The preparations may be in the form of emulsions, or aerosols for inhalation, of an oil or phospholipids or other derivatives or salts of omega-3-fatty acids of marine and/or vegetable origin with a significant content of omega-3-fatty acids. The preparations may also be in tablet or capsule form for oral use.

12 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 13. Document ID: US 5700654 A

L1: Entry 13 of 15

File: USPT

Dec 23, 1997

US-PAT-NO: 5700654

DOCUMENT-IDENTIFIER: US 5700654 A

TITLE: Method and compositions to assess oxidative stress in vivo

DATE-ISSUED: December 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roberts; L. Jackson	Nashville	TN		
Morrow; Jason D.	Nashville	TN		

US-CL-CURRENT: 435/25; 435/63, 436/71, 436/74, 562/503

ABSTRACT:

This invention relates to a method to assess oxidative stress in vivo by quantification of prostaglandin F.sub.2-like compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.

8 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KIMC
Draw Desc	Image									

☐ 14. Document ID: US 5686250 A

L1: Entry 14 of 15

File: USPT

Nov 11, 1997

US-PAT-NO: 5686250

DOCUMENT-IDENTIFIER: US 5686250 A

TITLE: Antibodies to LGE.sub.2 -protein antigens

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Salomon; Robert G.	Mayfield Village	OH		

US-CL-CURRENT: 435/7.1; 435/7.92, 436/13, 436/71, 436/88, 530/387.1

ABSTRACT:

Levuglandin (LG) derivatives are used as antigens for raising antibodies useful in diagnostic assays. The antibodies produced by LG-carrier protein adducts can be used to detect adducts of LGE.sub.2 with human low density lipoprotein (LDL). LGE.sub.2 -protein adduct immunoreactivity may be generated during in vitro free-radical oxidation of LDL. An enzyme-linked immunosorbent assay for detecting adducts of LGE.sub.2 with human LDL is also described.

20 Claims, 25 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 15. Document ID: WO 200032805 A1, AU 200031083 A, EP 1135519 A1

L1: Entry 15 of 15

File: DWPI

Jun 8, 2000

DERWENT-ACC-NO: 2000-412349
DERWENT-WEEK: 200035
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Measuring level of lipid peroxidation for diagnosing oxidant stress syndrome/disease such as Alzheimer's disease, involves comparing level of isoprostane molecule marker in samples from normal and diseased mammals

INVENTOR: FITZGERALD, G A; PRATICO, D ; ROKACH, J ; TROJANOWSKI, J Q

PRIORITY-DATA: 1998US-110569P (December 2, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200032805 A1	June 8, 2000	E	058	C12P031/00
AU 200031083 A	June 19, 2000		000	C12P031/00
EP 1135519 A1	September 26, 2001	E	000	C12P031/00

INT-CL (IPC): C12 P 31/00; C12 Q 1/26; G01 N 33/53

ABSTRACTED-PUB-NO: WO 200032805A

BASIC-ABSTRACT:

NOVELTY - Measuring level of lipid peroxidation in a mammal suspected of having an oxidant stress syndrome/disease (OS) involves comparing the level of isoprostane molecule marker (I) in samples (Ia) and (Ib) obtained from diseased and normal mammals respectively. An elevated level of (I) in (Ia) relative to the level in (Ib), indicates the presence of OS.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) identifying a compound (II) useful for the treatment of Alzheimer's disease (AD), involving comparing the level of (I) prior to and after administration of (II) in a mammal, where (II) which reduces the level of (I), is identified as the compound useful for treatment of AD;

(2) determining the optimal concentration or dosage frequency of (II) involving monitoring the level of (I) in a series of mammals administered with (II), at a series of concentration or dosage frequencies not toxic to the mammal, which results in maximal reduction of the level of (I), is the optimal concentration or optimal dosage frequency; and

(3) a kit for measuring level of (I) comprising:

(i) sample container for carrying a tissue or body fluid sample;

(ii) a solution for extraction of (I);

(iii) a negative and positive control solution of (I) obtained from a normal mammal and a mammal afflicted with Alzheimer's disease respectively;

- (iv) an antibody directed against (I); and
- (v) instructional material.

ACTIVITY - Nootropic; neuroprotective.

MECHANISM OF ACTION - None given.

USE - The method is useful for diagnosing oxidant stress syndrome or disease in a mammal involving measuring level of lipid peroxidation, and for identifying a compound and its effective dose, useful for treating Alzheimer's disease (claimed). The oxidative stress syndrome or disease is a neurodegenerative syndrome or disease such as, for example, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Down's syndrome, and Parkinson's disease (preferably Alzheimer's disease).

ADVANTAGE - The isoprostanes used as molecular markers of lipid peroxidation are chemically stable end products of lipid peroxidation, that are released by phospholipases circulated in the plasma and are excreted in the urine, when compared to the conventional indices of lipid peroxidation which rapidly decompose.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

Generate Collection

Print

Term	Documents
ISOPROSTANE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	9
ISOPROSTANES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	18
LIPID.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	45609
LIPIDS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	26209
PEROXIDATION.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	2820
PEROXIDN.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	63
COX.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	30392
COXES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	6
CYCLOOGENASE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	2
CYCLOOGENASES	0
(ISOPROSTANE AND (LIPID PEROXIDATION OR COX OR CYCLOOGENASE OR ALZHEIMER)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	15

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:

Change Format

[Previous Page](#)

[Next Page](#)